首页> 外文期刊>The American Journal of Cardiology >Patterns and Predictors of Evidence-Based Medication Continuation Among Hospitalized Heart Failure Patients (from Get With the Guidelines-Heart Failure).
【24h】

Patterns and Predictors of Evidence-Based Medication Continuation Among Hospitalized Heart Failure Patients (from Get With the Guidelines-Heart Failure).

机译:住院心力衰竭患者中循证药物继续用药的模式和预测因素(摘自《 Get with the Guidelines-心力衰竭》)。

获取原文
获取原文并翻译 | 示例
           

摘要

Hospitalized patients with heart failure and decreased ejection fraction are at substantial risk for mortality and rehospitalization, yet no acute therapies are proven to decrease this risk. Therefore, in-hospital use of medications proved to decrease long-term mortality is a critical strategy to improve outcomes. Although endorsed in guidelines, predictors of initiation and continuation of angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), beta blockers, and aldosterone antagonists have not been well studied. We assessed noncontraindicated use patterns for the 3 medications using the Get With the Guidelines-Heart Failure (GWTG-HF) registry from February 2009 through March 2010. Medication continuation was defined as treatment on admission and discharge. Multivariable logistic regression using generalized estimating equations was used to determine factors associated with discharge use. In total 9,474 patients were enrolled during the study period. Of those treated before hospitalization, overall continuation rates were 88.5% for ACE inhibitors/ARBs, 91.6% for beta blockers, and 71.9% for aldosterone-antagonists. Of patients untreated before admission, 87.4% had ACE inhibitors/ARBs and 90.1% had beta blocker initiated during hospitalization or at discharge, whereas only 25.2% were started on an aldosterone antagonist. In multivariate analysis, admission therapy was most strongly associated with discharge use (adjusted odds ratios 7.4, 6.0, and 20.9 for ACE inhibitors/ARBs, beta blockers, and aldosterone antagonists, respectively). Western region, younger age, and academic affiliation were also associated with higher discharge use. Although ACE inhibitor/ARB and beta-blocker continuation rates were high, aldosterone antagonist use was lower despite potential eligibility. In conclusion, being admitted on evidence-based medications is the most powerful, independent predictor of discharge use.
机译:患有心力衰竭和射血分数降低的住院患者有很高的死亡和再次住院风险,但尚无急性疗法可降低这种风险。因此,事实证明,院内使用药物可以降低长期死亡率,这是提高治疗效果的关键策略。尽管已在指南中得到认可,但尚未很好地研究血管紧张素转换酶(ACE)抑制剂/血管紧张素受体阻滞剂(ARB),β受体阻滞剂和醛固酮拮抗剂的起始和持续性的预测因素。从2009年2月至2010年3月,我们使用“获得指导-心脏衰竭”(GWTG-HF)注册中心评估了这3种药物的非禁忌使用模式。药物的持续使用定义为入院和出院治疗。使用广义估计方程进行多变量logistic回归来确定与排放使用相关的因素。在研究期间,总共招募了9,474名患者。在住院之前接受治疗的患者中,ACEI / ARBs的总持续率为88.5%,β受体阻滞剂的总持续率为91.6%,醛固酮拮抗剂的总持续率为71.9%。入院前未经治疗的患者中,有87.4%的患者在住院期间或出院时开始使用ACE抑制剂/ARB,90.1%的患者开始使用β受体阻滞剂,而醛固酮拮抗剂仅开始使用25.2%。在多变量分析中,入院治疗与出院使用最密切相关(ACE抑制剂/ ARB,β受体阻滞剂和醛固酮拮抗剂的调整优势比分别为7.4、6.0和20.9)。西部地区,较年轻的年龄和学术背景也与较高的出院率相关。尽管ACE抑制剂/ ARB和β受体阻滞剂的持续率很高,但是尽管有潜在的资格,醛固酮拮抗剂的使用仍较低。总之,以循证药物入院是出院使用的最有力,独立的预测因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号